A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
NCT ID: NCT04092452
Last Updated: 2023-06-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
194 participants
INTERVENTIONAL
2019-12-02
2022-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT04476043
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
NCT05997277
A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne Vulgaris
NCT06671834
Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa
NCT06301256
Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris
NCT02100527
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
PF-06650833
PF-06650833
400 mg QD
Cohort 2
PF-6700841
PF-06700841
45 mg QD
Cohort 3
PF-06826647
PF-06826647
400 mg QD
Cohort placebo
placebo
Placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-06650833
400 mg QD
PF-06700841
45 mg QD
PF-06826647
400 mg QD
Placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Infected with hepatitis B or hepatitis C viruses.
* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University Of Alabama At Birmingham
Birmingham, Alabama, United States
The University of Alabama at Birmingham Hospital Outreach Lab
Birmingham, Alabama, United States
The University of Alabama at Birmingham Investigation Drug Services Pharmacy
Birmingham, Alabama, United States
The University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic
Scottsdale, Arizona, United States
Center for Dermatology Clinical Research, Inc.
Fremont, California, United States
Pacific Clinical Trials
Long Beach, California, United States
Keck School of Medicine of University of Southern California
Los Angeles, California, United States
UCSF Dermatology Clinic
San Francisco, California, United States
University of California San Francisco
San Francisco, California, United States
UCSF Psoriasis and Skin Treatment Center
San Francisco, California, United States
Clinical Science Institute
Santa Monica, California, United States
New England Research Associates, LLC
Bridgeport, Connecticut, United States
Dermatology Physicians of Connecticut
Shelton, Connecticut, United States
Total Dermatology Care Center
Jacksonville, Florida, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, United States
Olympian Clinical Research Largo Office
Largo, Florida, United States
University of Miami Hospital
Miami, Florida, United States
Tory Sullivan MD PA
North Miami Beach, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
MidState Skin Institute
Ocala, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Park Avenue Dermatology
Orange Park, Florida, United States
Leavitt Medical Associates of Florida d/b/a Ameriderm Research
Ormond Beach, Florida, United States
Riverchase Dermatology and Cosmetic Surgery
Pembroke Pines, Florida, United States
ForCare Clinical Research
Tampa, Florida, United States
Alliance Clinical Research of Tampa
Tampa, Florida, United States
MedaPhase Inc.
Newnan, Georgia, United States
Advanced Medical Research PC
Sandy Springs, Georgia, United States
Georgia Skin Cancer and Aesthetic Dermatology
Watkinsville, Georgia, United States
NorthShore University HealthSystem Dermatology Clinic
Skokie, Illinois, United States
Ds Research
Clarksville, Indiana, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
DS Research
Louisville, Kentucky, United States
Boston Medical Center
Boston, Massachusetts, United States
Boston University General Clinical Research Unit
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Wayne State University / Integrative Biosciences Center
Detroit, Michigan, United States
Revival Research Institute, LLC
Troy, Michigan, United States
Clinical Research Unit
Minneapolis, Minnesota, United States
Lillihei Clinical Research Unit
Minneapolis, Minnesota, United States
University of Minnesota Department of Dermatology
Minneapolis, Minnesota, United States
MediSearch Clinical Trials
Saint Joseph, Missouri, United States
Saint Louis University - Department of Dermatology
St Louis, Missouri, United States
Skin Specialists PC
Omaha, Nebraska, United States
J Woodson Clinical Studies Group
Henderson, Nevada, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Vital Prospects Clinical Research Institute
Tulsa, Oklahoma, United States
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Penn State Health Radiology - University Physician Center
Hershey, Pennsylvania, United States
Paddington Testing Company, Inc
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Dermatology and Skin Cancer Consultants
Humboldt, Tennessee, United States
Clinical Research Solutions
Jackson, Tennessee, United States
Dermatology and Skin Cancer Consultants
Jackson, Tennessee, United States
Arlington Research Center
Arlington, Texas, United States
Austin Institute for Clinical Research, Inc.
Pflugerville, Texas, United States
University of Utah MidValley Dermatology
Murray, Utah, United States
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States
Bellevue Dermatology Clinical Research Center
Bellevue, Washington, United States
Bellevue Dermatology Clinic
Bellevue, Washington, United States
Dermatology Associates of Seattle
Seattle, Washington, United States
Woden Dermatology
Phillip, Australian Capital Territory, Australia
Premier Specialists Pty Ltd
Kogarah, New South Wales, Australia
Holdsworth House Medical Practice
Sydney, New South Wales, Australia
Veracity Clinical Research
Woolloongabba, Queensland, Australia
Skin Health Institute Inc.
Carlton, Victoria, Australia
Sinclair Dermatology
East Melbourne, Victoria, Australia
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, Canada
Manna Research (London)
London, Ontario, Canada
DermEffects
London, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
The Centre for Dermatology
Richmond Hill, Ontario, Canada
Diex Recherche Sherbrooke Inc.
Sherbrooke, Quebec, Canada
Centre de Recherche Saint-Louis
Québec, , Canada
Alpha Recherche Clinique
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kimball AB, Peeva E, Forman S, Moiin A, Khattri S, Porter ML, Mangold AR, Ghosh P, Banfield C, Oemar B. Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa. NEJM Evid. 2024 Mar;3(3):EVIDoa2300155. doi: 10.1056/EVIDoa2300155. Epub 2024 Feb 9.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C2501007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.